Contra-indicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with multiple endocrine neoplasia syndrome Type 2.
Xultophy is liraglutide and insulin degludec.
- TRADE NAMES: Saxenda (Novo Nordisk); Victoza (Novo Nordisk); Xultophy (Novo Nordisk)
- INDICATIONS:
To improve glycemic control in adults with Type II diabetes mellitus (Victoza).
Adjunct for the treatment of obesity and for weight loss management in defined populations and health conditions (Saxenda).
- CLASS: Anti-obesity / weight loss pharmacotherapy, Antidiabetic, Glucagon-like peptide-1 (GLP-1) receptor agonist
- HALF-LIFE: 13 hours
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acetaminophen, Atorvastatin, Digoxin, Griseofulvin, Lisinopril, Warfarin
- See adverse reactions attributed to class:
RISK OF THYROID C-CELL TUMORS
See full prescribing information for complete boxed warning.
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of the cardiovascular safety of liraglutide in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/28/2025
